Chemistry:Adarigiline
From HandWiki
Adarigiline (INN) is a monoamine oxidase inhibitor (MAOI) that was never marketed.[1][2][3][4] It is specifically a monoamine oxidase B (MAO-B) inhibitor.[1][2][3] This drug candidate was first described in 2009, in a patent assigned to Helicon Therapeutics.[5]
References
- ↑ 1.0 1.1 "-giline MAO-inhibitors type B C.3.1.0 (a) adarigiline (117),clorgiline (23), mofegiline (69), pargyline (13), rasagiline (70), selegiline (39), sembragiline (111)". Use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances (Stem book 2024). World Health Organization. 2024. p. 112. ISBN 978-92-4-009938-8. https://iris.who.int/bitstream/handle/10665/379226/9789240099388-eng.pdf.
- ↑ 2.0 2.1 "Proposed INN: List 117 International Nonproprietary Names for Pharmaceutical Substances (INN)". WHO Drug Information 31 (2). 2017. https://english.prescrire.org/Docu/DOCSDCI/WHO_INN_ProposedList117.pdf. "tadarigilinum adarigiline (4-hydroxypiperidin-1-yl){5-[4-methyl-5-(trifluoromethyl)- 1,2-oxazol-3-yl]thiophen-2-yl}methanone monoamine oxidase B inhibitor [...] C15H15F3N2O3S 1124197-79-0".
- ↑ 3.0 3.1 "Recommended INN: List 79 International Nonproprietary Names for Pharmaceutical Substances (INN)". WHO Drug Information 32 (1). 2018. https://iris.who.int/bitstream/handle/10665/330941/DI321-89-186-eng.pdf. "adarigilinum adarigiline (4-hydroxypiperidin-1-yl){5-[4-methyl-5-(trifluoromethyl)- 1,2-oxazol-3-yl]thiophen-2-yl}methanone [...] C15H15F3N2O3S".
- ↑ "ADARIGILINE". https://drugs.ncats.io/drug/YRT54V76ZY.
- ↑ Kaplan AP, Keenan TP, Mcriner AJ, "Therapeutic isoxazole compounds", WO patent 2009/029632A1, published 5 March 2009
 |  |
